Comparative Efficacy of Five SGLT2i on Cardiorenal Events: A Network Meta-analysis Based on Ten CVOTs
ConclusionsCanagliflozin, dapagliflozin, empagliflozin, ertugliflozin, and sotagliflozin versus placebo reduce HHF but none reduces MI and stroke. Canagliflozin is most effective in reducing MACE and HHF, and empagliflozin is most effective in reducing CVD, CVD or HHF, KFP, and ACD. These findings will guide the use of specific SGLT2i in the prevention of different cardiorenal events.
Source: American Journal of Cardiovascular Drugs - Category: Cardiology Source Type: research
More News: Canagliflozin | Cardiology | Cardiovascular | Dapagliflozin | Empagliflozin | Forxiga | Heart | Heart Attack | Heart Failure | Invokana | Jardiance | Sodium | Stroke | Urology & Nephrology